A meta-analysis of patient-level data from three randomized controlled trials involving patients with newly diagnosed multiple myeloma indicates that lenalidomide maintenance therapy significantly improves the outcomes of patients undergoing autologous stem-cell transplantation (ASCT). In this analysis, patients receiving lenalidomide had a median progression-free survival duration

中文翻译：

---

血液癌症：来那度胺可改善ASCT后的生存率

对来自三项涉及新诊断的多发性骨髓瘤的患者的随机对照试验的患者水平数据的荟萃分析表明，来那度胺维持治疗显着改善了接受自体干细胞移植（ASCT）的患者的结局。在此分析中，接受来那度胺的患者的中位无进展生存期